Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 41 publications
Sutimlimab for cold agglutinin disease: an updated perspective from approval to real-world clinical treatment.
Journal: Expert review of hematology
Published: July 08, 2026
Efficacy and Safety of Subcutaneous Efgartigimod PH20 in Adults With Primary Immune Thrombocytopenia (ADVANCE SC): A Multicenter, Randomized, Double-Blinded, Placebo-Controlled, Phase 3 Trial.
Journal: American journal of hematology
Published: March 09, 2026
Safety and Effectiveness of Sutimlimab in Cold Agglutinin Disease: A Real-World International Experience.
Journal: American journal of hematology
Published: January 30, 2026
Treatment of Cold Agglutinin Syndrome Secondary to Chronic Lymphocytic Leukemia With Sutimlimab and Obinutuzumab-Venetoclax.
Journal: Case reports in hematology
Published: January 21, 2026
Sutimlimab vs B-cell-targeted therapy in cold agglutinin disease: which is the optimal approach?
Journal: Blood
Published: January 16, 2026
Dual therapy: danicopan as add-on therapy to C5 inhibitors.
Journal: Clinical advances in hematology & oncology : H&O
Published: July 01, 2025
Practical approach to managing PNH: Q&A.
Journal: Clinical advances in hematology & oncology : H&O
Published: July 01, 2025
Navigating the paroxysmal nocturnal hemoglobinuria (PNH) landscape.
Journal: Clinical advances in hematology & oncology : H&O
Published: July 01, 2025
Monotherapy with upstream or alternative pathway inhibitors.
Journal: Clinical advances in hematology & oncology : H&O
Published: July 01, 2025
Safety profile of efgartigimod from global clinical trials across multiple immunoglobulin G-mediated autoimmune diseases.
Journal: Expert review of clinical immunology
Published: April 29, 2025
Ibrutinib and Venetoclax in Relapsed and Refractory Follicular Lymphoma.
Journal: Clinical lymphoma, myeloma & leukemia
Published: March 05, 2025
Efgartigimod for primary immune thrombocytopenia: the ADVANCE IV trial - Authors' reply.
Journal: Lancet (London, England)
Published: June 06, 2024
Last Updated: 09/26/2026